{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Severe non-hematologic adverse events were defined as adverse events grade 4 (life threatening or disabling) or grade 5 (death), regardless of attribution to study drug. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria (CTC) version 2.","groups":[{"description":"Patients in this outcome received both Anakinra (100mg daily subcutaneously administered) and dexamethasone (either 20mg/week OR 40mg days 1-4, 9-12, 17-20 every 28 days during odd cycles OR 40 mg days 1-4 every 28 days during even cycles)","id":"OG000","title":"Anakinra With Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Only participants who received Anakinra with low or high dose dexamethasone were analyzed.","reportingStatus":"POSTED","timeFrame":"every cycle during treatment (up to 5 years)","title":"Number of Patients With Severe Non-hematological Adverse Events in Participants Receiving Anakinra in Combination With Dexamethasone","type":"SECONDARY","unitOfMeasure":"participants"}